Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Multisystem Proteinopathies (MSP) and MSP-like Disorders: Clinical-Pathological-Molecular Spectrum and Long-term Follow Up
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - Poster Session 5 (11:45 AM-12:45 PM)
10-004

MSPs are genetically heterogenous disorders featured by neurodegeneration including amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD), inclusion body myopathy (IBM), and Paget disease of bone (PDB), sharing similar pathological findings of protein aggregation. Additional genes encoding RNA-binding proteins or proteins involved in quality-control pathways also lead to myopathy or neurodegeneration, although not necessarily within the same family, causing similar pathological abnormalities (MSP-like disorders).

To define phenotypic and genotypic spectrum of multisystem proteinopathies (MSP) and MSP-like disorders.

We searched Mayo Clinic database (1/1/2010-6/30/2022) to identify patients with mutations in genes causative of MSP and MSP-like disorders. Clinical and laboratory data were reviewed.

Thirty-one individuals (11 female) from 27 unrelated families were identified. Pathogenic mutations were in: VCP (17 patients/14 families), SQSTM1+TIA1 (5 patients/5 families), TIA1 (5 patients/4 families), MATR3, HNRNPA1, HSPB8, and TFG (1 patient each). Myopathy occurred in all but 2 VCP-MSP patients and was the initial presentation at median age of 52. Patterns of weakness were limb-girdle in 12/15 VCP-MSP and distal-predominant in the remaining patients. Twenty/24 muscle biopsies showed myopathy with rimmed vacuoles. MND and FTD occurred in 5 (4 VCP, 1 TFG) and 4 (3 VCP, 1 SQSTM1+TIA1) patients, respectively. PDB was present in 4 VCP-MSP.  Twenty-one patients had last echocardiogram 8 years (median; range 3-22 years) after disease onset showing diastolic dysfunction in 2 VCP-MSP patients. Six patients demonstrated restrictive ventilatory impairment 15 years after disease-onset. At median follow-up of 11.5 years, 15 patients were ambulating without gait-aids; loss of ambulation (n=5) and death (n=3) were recorded only in VCP-MSP patients.

Among MSP and MSP-related disorders, VCP was the most common causative gene, followed by SQSTM1+TIA1 and TIA1; myopathy with rimmed vacuoles was the most frequent manifestation; distal-predominant weakness occurred frequently in non-VCP-MSP;loss of ambulation was observed only in VCP-MSP at 11.5-year follow-up.
Authors/Disclosures
Pitcha Chompoopong, MD (University of Minnesota)
PRESENTER
Dr. Chompoopong has nothing to disclose.
Bjorn E. Oskarsson, MD, FAAN (Mayo Clinic) Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. The institution of Dr. Oskarsson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AnnJi. The institution of Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Oskarsson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Tsumura. The institution of Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MediciNova. The institution of Dr. Oskarsson has received research support from Biogen. The institution of Dr. Oskarsson has received research support from Medicinova. The institution of Dr. Oskarsson has received research support from Cytokinetics. The institution of Dr. Oskarsson has received research support from Calico. The institution of Dr. Oskarsson has received research support from Mitsubishi. The institution of Dr. Oskarsson has received research support from Tsumura. The institution of Dr. Oskarsson has received research support from Sanofi. The institution of Dr. Oskarsson has received research support from AZTherapeutics. The institution of Dr. Oskarsson has received research support from Orion. The institution of Dr. Oskarsson has received research support from Esaii.
Nicolas N. Madigan, MD Dr. Madigan has nothing to disclose.
Igal Mirman, MD Dr. Mirman has nothing to disclose.
Jennifer Marie Martinez-Thompson, MD (Mayo Clinic) Dr. Martinez-Thompson has nothing to disclose.
Teerin Liewluck, MD, FAAN (Department of Neurology, Mayo Clinic) Dr. Liewluck has nothing to disclose.
Margherita Milone, MD, FAAN (Mayo Clinic) Dr. Milone has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Milone has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics, AAN. The institution of Dr. Milone has received research support from Mayo Clinic, CCaTS-CBD. The institution of Dr. Milone has received research support from Mayo Clinic, SGP Award. The institution of Dr. Milone has received research support from MDA for Care Center grant. The institution of Dr. Milone has received research support from Regenerative medicine Minnesota.